Page 4 Company : Part II. R&D Time and Expenditure Profile A. Testing Time Profile Date Date Testing Long-Term Animal Toxicity Compound Suspended for Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials and Carcinogenicity Tests Synthesized Nonmarketed Generic Name (or or Isolated Compounds Initiated Completed Number of Initiated Completed Number of Initiated Completed Number of Initiated Completed drug code) (mm/dd/yy) (mm/dd/yy) (mm/dd/yy) (mm/dd/yy) Subjects (mm/dd/yy) (mm/dd/yy) Subjects (mm/dd/yy) (mm/dd/yy) Subjects (mm/dd/yy) (mm/dd/yy)
Page 4 Company : Part II. R&D Time and Expenditure Profile A. Testing Time Profile Generic Name (or drug code) Date Compound Synthesized or Isolated (mm/dd/yy) Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Long-Term Animal Toxicity and Carcinogenicity Tests Date Testing Suspended for Nonmarketed Compounds (mm/dd/yy) Initiated (mm/dd/yy) Completed (mm/dd/yy) Number of Subjects Initiated (mm/dd/yy) Completed (mm/dd/yy) Number of Subjects Initiated (mm/dd/yy) Completed (mm/dd/yy) Number of Subjects Initiated (mm/dd/yy) Completed (mm/dd/yy)